Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
28 févr. 2022 06h28 HE
|
Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Global Cardiology IT Workflow Solutions Market 2022-2026: A $1.3 Billion Opportunity Assessment
23 févr. 2022 04h53 HE
|
Research and Markets
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Wide...
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
31 janv. 2022 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80...
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
30 janv. 2022 16h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Demand: Global Computer-aided Drug Discovery Market Estimated to Surpass $7,914.2 Million by 2028, and Grow at a CAGR of 15.0% during the Forecast Period [224-Pages] | Divulge By Research Dive
25 janv. 2022 09h00 HE
|
Research Dive
New York, USA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Research Dive states that the global computer-aided drug discovery market is estimated to garner a revenue of $7,914.2 million by 2028, and rise at...
Casana Closes $30 Million Series B Funding to Accelerate Development of Novel Effortless Home Health Monitoring
21 janv. 2022 12h15 HE
|
Casana Care, Inc.
ROCHESTER, N.Y., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Casana, a healthcare technology firm that is reinventing in-home health monitoring, announced today that it has raised $30 million in Series B...
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
10 janv. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Opportunities: Computer-aided Drug Discovery Market Expected to Gather a Revenue of $7,914.2 Million by 2028, Growing at a CAGR of 15% from 2021 to 2028 [224-Pages] | Business study by Research Dive
04 janv. 2022 09h00 HE
|
Research Dive
New York, USA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD),...
Esperion Appoints Benjamin O. Looker as General Counsel
04 janv. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as...
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
30 déc. 2021 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind,...